Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy - Takeaways - MDSpire

Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy

  • By

  • Callie Deng

  • Karthik Reddy

  • Yue Liang

  • Nikhil Bommakanti

  • Julie Rosenthal

  • Yannis M. Paulus

  • March 9, 2026

  • 0 min

Share

  • 1

    Diabetic Retinopathy (DR) is a leading cause of preventable blindness, affecting millions globally and projected to increase significantly by 2050.

  • 2

    Ultra-widefield fluorescein angiography (UWF FA) allows for enhanced visualization of retinal non-perfusion, capturing more retinal surface area than traditional methods.

  • 3

    Intravitreal anti-VEGF agents are first-line treatments for diabetic macular edema and have shown improved outcomes when combined with pan-retinal photocoagulation.

  • 4

    Longitudinal studies using UWF FA have shown limited changes in non-perfusion despite significant improvements in diabetic retinopathy severity after treatment.

  • 5

    The study aims to quantify changes in retinal non-perfusion and neovascularization over time using UWF imaging to better assess treatment responses in DR.

Original Source(s)

Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy

  • by Callie Deng, Karthik Reddy, Yue Liang, Nikhil Bommakanti, Julie Rosenthal, Yannis M. Paulus

  • March 9, 2026

Related Content

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

Editorial: Addressing the Challenges of Diabetes Complications and Exploring Innovative Approaches

Steroid Strategies in Diabetic Macular Edema